

11 Jan 2021 | News

QUOTED. 11 January. Peter Wrighton-Smith.

by

PerkinElmer has agreed to buy Oxford Immunotec for \$591m to add the UK company's T-cell immunology expertise and proprietary tuberculosis testing technology to its line of infectious disease testing products. See what Oxford Immunotec's CEO Peter Wrighton-Smith said about it here.

“Access to PerkinElmer's global reach and automation experience will enable us to accelerate our growth journey and make a growing impact in the field of infectious disease.” – Peter Wrighton-Smith, CEO, Oxford Immunotec

- Find out more: [PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For \\$591M](#)

[Click here](#) for a free trial of *Medtech Insight*